top of page

Nelson Advisors: Is Oracle Cerner for sale? If so, who are the most likely acquirers in the current climate?

Writer: Nelson Advisors
Nelson Advisors
30 minutes ago
13 min read
Nelson Advisors: Is Oracle Cerner for sale? If so, who are the most likely acquirers in the current climate?
Nelson Advisors: Is Oracle Cerner for sale? If so, who are the most likely acquirers in the current climate?

The short answer


Oracle Health, the business built on Cerner, is not officially for sale. Oracle has announced no process, and every public statement since January says it is doubling down. Yet the question refuses to die, because Oracle's balance sheet keeps asking it.


The fair position in November 2026 is this: there is no auction, but there is a price. Oracle is spending far more on AI data centres than it generates in cash, has borrowed heavily to do it, and has already sold other non-core holdings. A $28.3 billion acquisition that is losing US hospital share and sits outside the AI infrastructure story is the obvious candidate if funding tightens again

.

If a deal does happen, the buyer is unlikely to be Microsoft, Google or Amazon. The most plausible outcome is a private equity consortium, probably with Oracle keeping a minority stake and the cloud hosting contract, and with the US government as an unavoidable third party at the table.


One caveat before the detail. Almost everything written about a sale traces back to a single analyst note from January 2026 and the commentary it set off. Nobody quoted below in our article claims inside knowledge of a sale process, and neither do we. The odds in this post are completely judgment based, not reporting based on any facts.


Where the rumour came from


The story started on 29th January 2026, when The Register reported a research note from investment bank TD Cowen. The note said Oracle was weighing several ways to fund its AI build-out. The options included cutting 20,000 to 30,000 jobs, vendor financing, and selling assets, with Cerner named as a possibility.


The arithmetic behind the note was simple. TD Cowen estimated that Oracle's OpenAI contract alone would need about $156 billion of capital spending. Banks were pulling back from Oracle-linked data centre lending, and the cost of insuring Oracle's debt was rising.


The numbers since then have not calmed anyone down:


  • Fiscal 2026 (June 2025 to May 2026). Capital spending reached about $55.7 billion against a $50 billion target, and free cash flow was negative $23.7 billion, according to Oracle's results and Reuters. Oracle raised $43 billion of debt and $5 billion of equity in the year.


  • Fiscal 2027 guidance. Oracle expects $90 billion to $95 billion of capital spending, with up to $70 billion of that funded from its own cash rather than customer prepayments.


  • Debt. Oracle carried about $125 billion of debt at the end of August 2026, CNBC reported, and its shares were down 22% for the year at that point.


Oracle's answer came at its Investor Day on 28 October. Management promised positive free cash flow in the second half of fiscal 2028 and at least $30 billion in fiscal 2029. It also capped new capital raises through fiscal 2030 at $20 billion, split evenly between equity and debt.


That plan is the reason a sale is not imminent. It is also the reason a sale stays on the table. The cap leaves little slack, and Oracle reportedly used the whole $20 billion within about two weeks. If capital spending overshoots again, as it did in fiscal 2026, asset sales are the remaining release valve.


Oracle has already shown it will pull that lever. Its fiscal 2026 results included gains from selling its Ampere chip stake and its Bloom Energy warrants.


The case that Oracle sells


Five things have gone wrong for Oracle Health in 2026, on top of the parent company's cash needs.


US market share keeps falling. Oracle Health lost a net 56 hospitals and 14,676 beds in 2025, its third straight year of the largest losses of any vendor, according to KLAS data reported by Fierce Healthcare. Its share of US acute care hospitals is 21.9%, down from 25% in 2020. Epic holds 43.7% of hospitals and 56.9% of beds. Over five years Epic has gained a net 568 hospitals while Oracle Health has lost 173, healthsystemCIO noted. Moffitt Cancer Center and Westchester Medical Center Health Network both chose Epic this August.


The international story is mixed. KLAS's global report credited Oracle Health with wins in Canada, Austria and the Middle East. It also validated 34 hospital losses, more than half of them tied to a failed implementation in Sweden, Healthcare IT News reported.


People have left. Bloomberg reported early this year that five senior executives sent in to fix Cerner had departed, as Telehealth and Telecare Aware summarised. Trade coverage describes deep cuts to the health division in March as part of Oracle's wider layoffs. In August, Seema Verma, who runs Oracle Health, was rumoured to be a candidate to lead the drug industry lobby PhRMA. She was still presenting Oracle's roadmap in late September.


A large breach surfaced. In October, the Texas attorney general's office disclosed that a 2025 intrusion into legacy Cerner servers affected nearly 20 million people, according to coverage citing Bloomberg. The servers had not yet been moved to Oracle's cloud.


The federal contract is under political fire again. In October, the association representing the Department of Veterans Affairs' 20,000 doctors and dentists asked Congress to pause further deployments pending an independent safety review. The VA is seeking $17 billion more for the programme, and Oracle co-CEO Mike Sicilia and Larry Ellison are due before congressional committees on 19 November and 10 December, Telehealth and Telecare Aware reported. Democrats won control of Congress in last week's midterms, so oversight is likely to get sharper in 2027.


Put together, the sell case says healthcare is a slow, regulated, services-heavy distraction from an infrastructure race that Oracle cannot afford to lose. HFS Research made that argument as far back as January 2025, calling for a spin-off or a retreat to international markets.


The case that Oracle keeps it


The keep case is stronger than the headlines suggest, and it has improved since the summer.


Oracle keeps saying healthcare is core. Verma answered the January rumours within days, telling her LinkedIn followers that Oracle remained committed and expected more momentum this year. In June, Oracle's results statement said a new AI version of the Cerner system should push Oracle Health's growth into double digits in fiscal 2027. The September results release gave a headline slot to a fully agentic health records system, and management told analysts the health business continued to accelerate. Companies preparing to sell a division rarely put it in the shop window like that, though it must be said that they sometimes do exactly that to lift the price.


Some customers are choosing to stay. Kern Medical in California went to tender intending to switch vendor, then signed with Oracle Health for another eight and a half years from 1 August, Becker's reported last week. Baystate Health expanded its contract in June. AtlantiCare says consistent users of Oracle's Clinical AI Agent cut documentation time by about 40%. These are retention wins, not conquests, but retention is what a shrinking base needs first.


The VA rollout finally worked on schedule. The VA completed all 13 planned deployments for 2026 on 24 October, Nextgov reported, taking the system to 19 of roughly 170 medical centres. The VA's deputy secretary told Congress the restart was on track and ahead of expectations. A programme with a proposed $4.2 billion in the fiscal 2027 budget and a 2031 finish line is valuable, sticky revenue.


Healthcare feeds the cloud. Every Cerner customer moved onto Oracle Cloud Infrastructure is a captive, long-term workload. Selling the application would put that workload in someone else's hands unless the hosting contract is written into the deal.


The proceeds would not solve the problem. This is the point most commentary misses. A sale at the $20 billion to $25 billion mooted by one advisory firm would cover roughly a quarter of a single year's capital spending. Oracle would book a loss on its largest ever acquisition, hand a rival or a fund its healthcare data position, and still need the bond market. A sale helps at the margin. It does not change the funding picture.


So Oracle has reasons to hold that are financial as well as reputational. The question is whether those reasons survive another capital spending overshoot or a bad outcome in Washington.


What would actually be sold, and for how much


"Cerner" no longer exists as a tidy unit, which is the first obstacle to any deal. A buyer would be looking at four different businesses:


  • The US commercial EHR base. The legacy Millennium platform, the new AI-based record, revenue cycle and population health tools. This is the shrinking but still large core.


  • The federal business. The VA programme, plus the Defense Department's completed deployment, which Cerner delivered as part of a Leidos-led partnership. The two systems must stay interoperable.


  • International. Long-standing customers in the UK, the Middle East, Canada and parts of Europe.


  • Oracle's own additions. The Clinical AI Agent and the rebuilt record run on Oracle's cloud and database. Life sciences and payer software predate the Cerner deal and would probably stay with Oracle.


Oracle does not publish Oracle Health's revenue. Cerner reported about $5.5 billion in 2020, its last full year before the deal was agreed. HFS Research estimated the unit at roughly 10% of Oracle's revenue in fiscal 2024. A figure in the region of $5 billion to $6 billion is a reasonable working assumption, but it is an assumption.


On price, the only public estimate comes from London advisory firm Nelson Advisors, whose June analysis was summarised by Telehealth and Telecare Aware. It put a consortium deal at $20 billion to $25 billion. That is around four times my assumed revenue and below the $28.3 billion Oracle paid in 2022, before counting what it has invested since.


Three things will pull that number around. A buyer will discount for the breach and any liabilities that follow it. Federal contracts cannot simply change hands without the government's consent. And the price rises if Oracle keeps the hosting and database revenue, because the buyer is then paying for the application business alone.


Nelson Advisors: Is Oracle Cerner for sale? If so, who are the most likely acquirers in the current climate?
Nelson Advisors: Is Oracle Cerner for sale? If so, who are the most likely acquirers in the current climate?

The most likely acquirers, ranked


Two outside analyses have ranked the field: Signify Research in February and Nelson Advisors in June. They reach the same conclusion from different directions. Financial buyers lead, technology giants trail, and healthcare incumbents barely register. Signify also gave Oracle a 45% chance of keeping the business outright.


The ranking below is mine. The odds column is Signify's February estimate where it gave one.


Rank

Buyer type

Named candidates

Why it works

What stops it

Signify odds

1

Private equity consortium, with Oracle keeping a minority stake and the hosting

Thoma Bravo, Francisco Partners, Bain Capital, Blackstone, New Mountain Capital

Frees cash, keeps cloud revenue, keeps the vendor neutral

Shared governance; funds need an exit

20%

2

Private equity consortium, full buyout

The same firms

Clean break and a turnaround thesis

Raising $20 billion or more; turnarounds in health IT are slow

20%

3

Break-up into federal, international and US commercial pieces

Government integrators, regional vendors, funds

Each piece has a more natural owner

One shared code base; VA and Defense systems must stay interoperable

Not modelled

4

Health IT peer

None named

Understands the business

Too large for most; antitrust for the one that could afford it

2% to 3%

5

Technology platform

Microsoft, Google, Amazon, Salesforce, Palantir

Combines AI with clinical workflow

Loss of neutrality, Epic relationships, antitrust

1% to 2% each

6

Payer, hospital group or foreign software firm

UnitedHealth and Optum, HCA, CommonSpirit, SAP

Vertical integration or global reach

Conflicts of interest, thin capital, no US federal track record

1% or less


Private equity is the natural home. Oracle Health is a large, cash-generating, under-managed software business with a locked-in customer base. That is the textbook buyout target. Nelson's view is that no single firm could write the cheque, so a consortium is needed, and that a turnaround story is essential to hold it together. The weak point is the exit. Funds buy to sell, and it is not obvious who buys this asset from them in seven years.


Why the hybrid version ranks first. A structure in which Oracle keeps a minority stake and the cloud contract answers Oracle's two best reasons for holding on. It keeps the hosting revenue and keeps a share of any recovery. It also lowers the amount the consortium has to raise. Customers get a vendor that is not owned by a rival cloud or a payer. I rank it above a clean buyout for those reasons, although Signify scored the two equally.


Washington is the kingmaker. Whoever buys inherits the VA and Defense programmes, and the government has to be comfortable with the new owner. That favours US owners able to meet federal security requirements and disfavours payers and foreign bidders. With Oracle's leadership due before Congress this month and next, and a new Congress arriving in January, a buyer would want the VA's direction settled before signing anything.


A break-up is the scenario nobody has priced. This is my own addition, and it is speculative. The federal business would suit a government integrator already working on the programme. The international business could be sold regionally, as Cerner did in 2020 when it sold its German and Spanish units to CompuGroup Medical for €255 million. The difficulty is that all three pieces run on the same platform, so separation would be slow and contractually messy.


Big technology firms are capable but conflicted. Microsoft is the most logical on paper, given Nuance and Azure. But it is deeply partnered with Epic, and its healthcare strategy depends on selling to every EHR vendor, not owning one. Amazon and Google face the same neutrality problem, plus little experience running a regulated, services-heavy records business. All three are also in their own capital spending races, which makes a $20 billion detour into hospital software a hard sell to their shareholders.


The outsiders are outsiders for good reason. A payer owning the clinical system of the hospitals it negotiates against would drive customers away and invite regulators in. Hospital groups lack the borrowing power. SAP would bring international reach but no experience of US federal health contracts. Among health IT peers, most are too small, and Epic neither buys competitors nor would be allowed to.


Signals to watch


A sale will not arrive without warning. These are the markers that would move the odds over the next six months.


  • Oracle's December results. Capital spending running ahead of the $70 billion net cap would put the funding plan under strain within weeks of its launch.


  • The congressional hearings on 19th November and 10th December. A forced pause at the VA would damage the most valuable contract in the unit. A clean bill of health would make it far easier to sell.


  • The promised double-digit growth. Oracle said fiscal 2027 would deliver it. If the claim quietly disappears from results statements, the turnaround case weakens.


  • Seema Verma's position. A change at the top of Oracle Health, in either direction, would say something about intent.


  • KLAS's next US market share report, due around May 2027. A fourth year of heavy losses would cut the price. Evidence that the new record is stemming defections would raise it.


  • Accounting and adviser clues. Reorganising Oracle Health into a separate legal or reporting unit, or reports of banks being hired, are the classic precursors to a carve-out.


The verdict


Is Oracle Cerner for sale? Not today, and not officially. Oracle has a funding plan, a new product to prove, and a federal rollout that finally hit its dates. Those are reasons to wait.


But the business is more sellable than at any time since 2022. Its parent has a hard cap on new borrowing, a record of monetising non-core assets, and a core strategy in which hospital software is at best adjacent. My own estimate is roughly a one in three chance of a change of control by the end of 2027. That is a judgment call, and it is lower than Signify's February figure because Oracle has since bought itself time.


If it happens, expect private equity money, an Oracle minority stake, a long-term hosting agreement, and a great deal of quiet conversation with the VA and the Pentagon first. Do not expect a hyperscaler.


For hospitals running Oracle Health, the practical advice does not depend on the outcome. Check what your contract says about change of control, roadmap commitments and hosting terms, and ask for those protections at your next renewal. Ownership may or may not change. The leverage to ask is there either way.


Sources



Nelson Advisors > European Healthcare Technology Investment Banking


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk


Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital 


Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb 



Nelson Advisors LLP


Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT




Meet Nelson Advisors @ Events in 2026


Digital Health Rewired > March 2026 > Birmingham, UK  


NHS ConfedExpo  > June 2026 > Manchester, UK 


HLTH Europe > June 2026, Amsterdam, Netherlands


HIMSS AI in Healthcare > July 2026, New York, USA


Bits & Pretzels > September 2026, Munich, Germany  


HealthInvestor Healthcare Summit > September 2026, London, UK 


World Health Summit 2026 > October 2026, Berlin, Germany


HLTH USA 2026 > October 2026, USA


Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia


Web Summit 2026 > November 2026, Lisbon, Portugal  


MEDICA 2026 > November 2026, Düsseldorf, Germany


Leaders in Health Summit 2026 > November 2026, London, UK 


Venture Capital World Summit > December 2026, Toronto, Canada


Meet Nelson Advisors @ Events in 2027


Digital Health Rewired > March 2027 > Birmingham, UK


Barclays Health Elevate > March 2027, London, UK 


NHS ConfedExpo  > June 2027 > Manchester, UK 


HLTH Europe > June 2027, Amsterdam, Netherlands


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page